Edwards Lifesciences (EW)
(Delayed Data from NYSE)
$86.43 USD
-1.58 (-1.80%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $86.49 +0.06 (0.07%) 7:58 PM ET
3-Hold of 5 3
D Value F Growth B Momentum F VGM
Income Statements
Fiscal Year end for Edwards Lifesciences Corporation falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 6,005 | 5,382 | 5,233 | 4,386 | 4,348 |
Cost Of Goods | 1,380 | 1,080 | 1,249 | 1,081 | 1,114 |
Gross Profit | 4,625 | 4,302 | 3,984 | 3,306 | 3,234 |
Selling & Adminstrative & Depr. & Amort Expenses | 3,091 | 2,554 | 2,293 | 2,408 | 2,087 |
Income After Depreciation & Amortization | 1,534 | 1,749 | 1,690 | 898 | 1,147 |
Non-Operating Income | 82 | 38 | 30 | 35 | 40 |
Interest Expense | 18 | 19 | 18 | 16 | 21 |
Pretax Income | 1,598 | 1,767 | 1,702 | 917 | 1,167 |
Income Taxes | 199 | 246 | 199 | 93 | 120 |
Minority Interest | -3 | 0 | 0 | 0 | 0 |
Investment Gains/Losses | 0 | 0 | 0 | 0 | 0 |
Other Income/Charges | 0 | 0 | 0 | 0 | 0 |
Income From Cont. Operations | 1,399 | 1,522 | 1,503 | 823 | 1,047 |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
Net Income (GAAP) | 1,402 | 1,522 | 1,503 | 823 | 1,047 |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | 1,679 | 1,888 | 1,825 | 1,005 | 1,236 |
Depreciation & Amortization (Cash Flow) | 145 | 140 | 135 | 107 | 89 |
Income After Depreciation & Amortization | 1,534 | 1,749 | 1,690 | 898 | 1,147 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 609.40 | 624.20 | 631.20 | 631.90 | 636.60 |
Diluted EPS Before Non-Recurring Items | 2.51 | 2.48 | 2.22 | 1.86 | 1.86 |
Diluted Net EPS (GAAP) | 2.30 | 2.44 | 2.38 | 1.30 | 1.64 |
Fiscal Year end for Edwards Lifesciences Corporation falls in the month of December .
All items in Millions except EPS data.
3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 | |
---|---|---|---|---|---|
Sales | NA | 1,534.10 | 1,480.90 | 1,530.20 | 1,459.60 |
Cost Of Goods | NA | 356.90 | 350.40 | 343.00 | 329.50 |
Gross Profit | NA | 1,177.20 | 1,130.50 | 1,187.20 | 1,130.10 |
SG&A, R&D, and Dept/Amort Expenses | 0.00 | 777.10 | 712.10 | 860.00 | 741.70 |
Income After SG&A, R&D, and Dept/Amort Expenses | 0.00 | 400.10 | 418.40 | 327.20 | 388.40 |
Non-Operating Income | NA | 39.20 | 20.90 | 11.30 | 10.20 |
Interest Expense | NA | 17.60 | 0.00 | 0.00 | 0.00 |
Pretax Income | NA | 421.70 | 439.30 | 338.50 | 398.60 |
Income Taxes | NA | 52.00 | 55.60 | 33.00 | 58.10 |
Minority Interest | NA | -0.20 | -1.20 | -1.60 | 0.00 |
Investment Gains/Losses | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | NA | 369.70 | 383.70 | 305.50 | 340.50 |
Extras & Discontinued Operations | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | NA | 369.90 | 384.90 | 307.10 | 340.50 |
Earnings Per Share Data | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 |
---|---|---|---|---|---|
Average Shares | NA | 606.90 | 609.50 | 610.30 | 610.90 |
Diluted EPS Before Non-Recurring Items | NA | 0.64 | 0.59 | 0.66 | 0.62 |
Diluted Net EPS (GAAP) | NA | 0.61 | 0.63 | 0.50 | 0.56 |